کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
3945540 1254268 2016 8 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Performance of AGO score for secondary cytoreduction in a high-volume U.S. center
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی زنان، زایمان و بهداشت زنان
پیش نمایش صفحه اول مقاله
Performance of AGO score for secondary cytoreduction in a high-volume U.S. center
چکیده انگلیسی


• AGO score correlates with complete cytoreduction, but negative predictive value is low
• Disease-free interval, number of recurrence sites increase AGO score predictive value
• DFI, recurrence pattern, ECOG PS may predict OS after complete secondary cytoreduction

ObjectivesDetermine the predictive value of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) score, and prognostic factors for survival, in patients undergoing secondary cytoreductive surgery (SCS) for recurrent ovarian cancer in a high-volume U.S. center.MethodsMedical records of women undergoing SCS between 12/1/1998 and 12/31/2013 were reviewed. Women with no gross residual disease (RD0) at primary surgery, ECOG performance status (PS) ≤ 1 at recurrence, and no ascites on CT at recurrence were classified as AGO score positive. Women with incomplete information to determine the AGO score were excluded. Overall survival (OS) and progression-free survival (PFS) following SCS, respectively, were estimated from multivariable Cox proportional hazards models.Results192 women met inclusion criteria. Median disease-free interval (DFI) was 1.9 years (IQR, 1.0–3.5). Of the 102 (53.1%) AGO score positive cases, 84.3% (95% CI, 77.3–91.4%) achieved RD0 at SCS. However, 64.4% of AGO score negative cases also reached RD0. Patients with RD0 after SCS survived longer (median OS, 5.4 years) vs. RD ≤ 1 cm (2.4 years) vs. RD > 1 cm (1.3 years) (p < 0.001). Median PFS was also longer in patients with RD0 (1.5 years) vs. RD ≤ 1 cm (0.9 years) vs. RD > 1 cm (1.0 years) (p = 0.001). Among those with RD0 at SCS, AGO score was not associated with survival benefit, however, number of disease sites at recurrence, ECOG PS at recurrence, and DFI were associated with OS and PFS.ConclusionsAGO score can identify patients with a high likelihood of complete secondary cytoreduction and improved survival. However, most AGO score negative cases were also completed resected at SCS. Additional refinement of the score is needed to exclude women from SCS.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Gynecologic Oncology - Volume 141, Issue 1, April 2016, Pages 140–147
نویسندگان
, , , , ,